Intrinsiqs

Is Tarsus Pharmaceuticals, Inc. overvalued?

Tarsus Pharmaceuticals, Inc. (TARS) — key valuation metrics and fundamentals.

No verdict
Price
$80.28
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$3.96B
Dividend yield
0.0%
Return on equity
-245.7%
Sector
Healthcare

See the full interactive analysis →

Fair value compares TARS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.